Rapport Therapeutics, Inc. (RAPP) short interest & options flow
NASDAQRapport Therapeutics reports today, November 6, with its stock down 26% over the past month and trading at $23.72, more than 60% below the analyst consensus target. That gap is striking for a company whose lead asset, RAP-219, cleared Phase 2 in bipolar mania with a 3.1-point placebo-adjusted YMRS improvement and no severe adverse events. What makes today's print different from a…
RAPP cost to borrow doubles to 0.85% in one week, rising from 0.42%, as short availability climbs sharply to 1289% of estimated short interest.
- Market cap
- $1.54B
- Next earnings
- 10 Mar 2027
Key data as of 11 Nov 2026
Latest signals on RAPP
- Cost to Borrow
RAPP cost to borrow doubles to 0.85% in one week, rising from 0.42%, as short availability climbs sharply to 1289% of estimated short interest.
- Short Interest
RAPP short interest surges 38% in one week to 6.6% of float, highest level since early October as stock slides 10%.
3 Short Interest updates in 30 days
RAPP news and analysis
RSSNo long-form analysis yet for RAPP. Pulse alerts and the live data picture are available on ORTEX.
Open RAPP on ORTEX →Want the live picture for RAPP?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RAPP — free to start on ORTEX.
Sign up for free →Open RAPP on ORTEX